An FDA Signal: Good News for California's Stem Cell Agency's Search for Therapies
The California stem cell agency this week highlighted a couple of milestones that it suggests may be creating a trend towards wider application of its research.
The springboard was an announcement that the Food and Drug Administration (FDA) had granted a "rare pediatric disease designation" to a therapy that the agency has backed with nearly $52 million.
Keep reading with a 7-day free trial
Subscribe to The California Stem Cell Report to keep reading this post and get 7 days of free access to the full post archives.